MX2025014306A - Nuevas opciones sinteticas hacia la manufactura de (6r,10s)-10-{4-[5-cloro-2-(4-cloro-1h-1,2,3-triazol-1-il)fenil]-6-oxo-1(6h)-pirimidinil}-1-(difluorometil)-6-metil-1,4,7,8,9,10-hexahidro-11,15-(meteno)pirazol[4,3-b][1,7]diazaciclotetradecin-5(6h)-ona - Google Patents

Nuevas opciones sinteticas hacia la manufactura de (6r,10s)-10-{4-[5-cloro-2-(4-cloro-1h-1,2,3-triazol-1-il)fenil]-6-oxo-1(6h)-pirimidinil}-1-(difluorometil)-6-metil-1,4,7,8,9,10-hexahidro-11,15-(meteno)pirazol[4,3-b][1,7]diazaciclotetradecin-5(6h)-ona

Info

Publication number
MX2025014306A
MX2025014306A MX2025014306A MX2025014306A MX2025014306A MX 2025014306 A MX2025014306 A MX 2025014306A MX 2025014306 A MX2025014306 A MX 2025014306A MX 2025014306 A MX2025014306 A MX 2025014306A MX 2025014306 A MX2025014306 A MX 2025014306A
Authority
MX
Mexico
Prior art keywords
synt
novel
synthesis
variety
compound
Prior art date
Application number
MX2025014306A
Other languages
English (en)
Spanish (es)
Inventor
Nicolas Cuniere
Yu Fan
Sergei Kolotuchin
Subha Mukherjee
Eric M Simmons
Amarjit Singh
Carolyn S Wei
Yi Xiao
Changxia Yuan
Bin Zheng
Simon Albert Wagschal
Diego Fernando Domenico Broggini
Duy Chi Trung Cao
Kostiantyn Chernichenko
Sébastien François Emmanuel LEMAIRE
Haïm Cyril Ben
Original Assignee
Bristol Myers Squibb Co
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co, Janssen Pharmaceutica Nv filed Critical Bristol Myers Squibb Co
Publication of MX2025014306A publication Critical patent/MX2025014306A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2025014306A 2019-04-11 2020-04-10 Nuevas opciones sinteticas hacia la manufactura de (6r,10s)-10-{4-[5-cloro-2-(4-cloro-1h-1,2,3-triazol-1-il)fenil]-6-oxo-1(6h)-pirimidinil}-1-(difluorometil)-6-metil-1,4,7,8,9,10-hexahidro-11,15-(meteno)pirazol[4,3-b][1,7]diazaciclotetradecin-5(6h)-ona MX2025014306A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962832614P 2019-04-11 2019-04-11
PCT/US2020/027655 WO2020210613A1 (en) 2019-04-11 2020-04-10 Novel synthetic options towards the manufacture of (6r,10s)-10- {4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6h)- pyrimidinyl}- 1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15 -(metheno)pyrazolo [4,3-b] [1,7] diazacyclotetradecin-5(6h)-one

Publications (1)

Publication Number Publication Date
MX2025014306A true MX2025014306A (es) 2026-01-07

Family

ID=70457148

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2025014306A MX2025014306A (es) 2019-04-11 2020-04-10 Nuevas opciones sinteticas hacia la manufactura de (6r,10s)-10-{4-[5-cloro-2-(4-cloro-1h-1,2,3-triazol-1-il)fenil]-6-oxo-1(6h)-pirimidinil}-1-(difluorometil)-6-metil-1,4,7,8,9,10-hexahidro-11,15-(meteno)pirazol[4,3-b][1,7]diazaciclotetradecin-5(6h)-ona
MX2021012286A MX2021012286A (es) 2019-04-11 2020-04-10 Nuevas opciones sinteticas hacia la manufactura de (6r,10s)-10-{4-[5-cloro-2-(4-cloro-1h-1,2,3-triazol-1-il)fenil]-6 -oxo-1(6h)-pirimidinil}-1-(difluorometil)-6-metil-1,4,7,8,9,10-he xahidro-11,15-(meteno)pirazol[4,3-b][1,7]diazaciclotetradecin-5(6 h)-ona.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021012286A MX2021012286A (es) 2019-04-11 2020-04-10 Nuevas opciones sinteticas hacia la manufactura de (6r,10s)-10-{4-[5-cloro-2-(4-cloro-1h-1,2,3-triazol-1-il)fenil]-6 -oxo-1(6h)-pirimidinil}-1-(difluorometil)-6-metil-1,4,7,8,9,10-he xahidro-11,15-(meteno)pirazol[4,3-b][1,7]diazaciclotetradecin-5(6 h)-ona.

Country Status (16)

Country Link
US (2) US12378246B2 (cg-RX-API-DMAC7.html)
EP (2) EP4234555A3 (cg-RX-API-DMAC7.html)
JP (2) JP7631218B2 (cg-RX-API-DMAC7.html)
KR (2) KR20260047658A (cg-RX-API-DMAC7.html)
CN (2) CN114375290B (cg-RX-API-DMAC7.html)
AR (1) AR118649A1 (cg-RX-API-DMAC7.html)
AU (2) AU2020272973B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021020368A2 (cg-RX-API-DMAC7.html)
CA (1) CA3132365A1 (cg-RX-API-DMAC7.html)
EA (1) EA202192807A1 (cg-RX-API-DMAC7.html)
ES (1) ES2969253T3 (cg-RX-API-DMAC7.html)
IL (1) IL287102B2 (cg-RX-API-DMAC7.html)
MX (2) MX2025014306A (cg-RX-API-DMAC7.html)
SG (1) SG11202111132WA (cg-RX-API-DMAC7.html)
TW (1) TWI880924B (cg-RX-API-DMAC7.html)
WO (1) WO2020210613A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11788071B2 (en) 2020-04-10 2023-10-17 Codexis, Inc. Engineered transaminase polypeptides
EP4225757A1 (en) * 2020-10-12 2023-08-16 Bristol-Myers Squibb Company A process toward the manufacture of (6r,10s)-10-{4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6h)-pyrimidinyl}-1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15-(metheno)pyrazolo[4,3-b] [1,7]diazacyclotetradecin-5(6h)-one

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013033777A2 (pt) * 2011-03-15 2016-09-13 Abbvie Inc moduladores de receptor de hormônio nuclear
JP6505727B2 (ja) 2014-01-31 2019-04-24 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company ヘテロ環式p2’基を有する第xia因子阻害剤としてのマクロ環
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
NO2721243T3 (cg-RX-API-DMAC7.html) * 2014-10-01 2018-10-20
CN105294496A (zh) 2015-09-28 2016-02-03 中山大学 一种西酞普兰中间体的制备方法
CN110062757B (zh) 2017-01-18 2022-03-04 广东东阳光药业有限公司 凝血因子XIa抑制剂及其用途
CN113677682B (zh) 2019-04-16 2023-05-30 华润生物医药有限公司 作为XIa因子抑制剂的大环衍生物
WO2021013209A1 (zh) 2019-07-23 2021-01-28 南京明德新药研发有限公司 作为XIa因子抑制剂的大环衍生物
CA3179679A1 (en) 2020-04-10 2021-10-14 Codexis, Inc. Carboxyesterase polypeptides for kinetic resolution

Also Published As

Publication number Publication date
MX2021012286A (es) 2022-04-06
BR112021020368A2 (pt) 2021-12-07
JP2025084766A (ja) 2025-06-03
US20260092066A1 (en) 2026-04-02
KR20220045105A (ko) 2022-04-12
TW202104188A (zh) 2021-02-01
CA3132365A1 (en) 2020-10-15
JP2022526659A (ja) 2022-05-25
US12378246B2 (en) 2025-08-05
EP3953334A1 (en) 2022-02-16
IL287102B2 (en) 2025-12-01
AR118649A1 (es) 2021-10-20
WO2020210613A1 (en) 2020-10-15
EP4234555A2 (en) 2023-08-30
AU2026201396A1 (en) 2026-03-19
TWI880924B (zh) 2025-04-21
IL287102B1 (en) 2025-08-01
EA202192807A1 (ru) 2022-02-24
CN119775276A (zh) 2025-04-08
US20220144836A1 (en) 2022-05-12
IL287102A (en) 2021-12-01
SG11202111132WA (en) 2021-11-29
CN114375290A (zh) 2022-04-19
AU2020272973A1 (en) 2021-12-02
KR20260047658A (ko) 2026-04-08
KR102929951B1 (ko) 2026-02-24
EP3953334B1 (en) 2023-11-22
CN114375290B (zh) 2024-11-29
EP4234555A3 (en) 2024-01-03
JP7885383B2 (ja) 2026-07-06
JP7631218B2 (ja) 2025-02-18
AU2020272973B2 (en) 2025-11-27
ES2969253T3 (es) 2024-05-17

Similar Documents

Publication Publication Date Title
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
CO2021016967A2 (es) Nuevos inhibidores de egfr
BR112019003637A2 (pt) um esteróide 19-nor c3,3-dissubstituído c21-n-pirazolil cristalino
CL2019002792A1 (es) Composición para producir tagatosa y procedimiento de producción de tagatosa usando el mismo.
CO2021002954A2 (es) Anticuerpos anti-αvβ8 y composiciones y usos de los mismos
CL2022001492A1 (es) Nuevos inhibidores de braf como rompedores de la paradoja
MX2019011758A (es) Composicion para producir tagatosa y procedimiento de produccion de tagatosa usando la misma.
CL2017003021A1 (es) Agentes de unión a inmunorreceptor de células t con dominios ig y motivo de inhibición basado en tirosina de inmunorreceptor (tigit) y usos de los mismos.
CO2021011906A2 (es) Anticuerpos claudina 6 y usos de los mismos
ECSP21053104A (es) Moduladores de la expresión de hsd17b13
CR20160419A (es) Nuevos compuestos biciclicos
BR112017018276A2 (pt) ?composição que compreende peptidase e biotensoativo e seu uso?
MX2019004740A (es) Composicion bucal de fases multiples para el cuidado bucal.
MX2021003180A (es) Métodos y kits para preparar sangre entera con inactivación de patógenos.
NI202000087A (es) Anticuerpos ant-tmeff2 monoespecíficos y multiespecíficos y sus usos
MX2019011730A (es) Composicion para producir tagatosa y procedimiento de produccion de tagatosa usando la misma.
CY1125297T1 (el) Αναστολεις της il-8 για χρηση στην αγωγη της περιφερικης νευροπαθειας που επαγεται απο χημειοθεραπεια
MX2019010643A (es) Formas y composiciones de un inhibidor de proteina cinasa 2 activada por la proteina cinasa activada por mitogeno (mk2).
CO2022006965A2 (es) Inhibidores de egfr
MX390725B (es) Kits y metodos para preparar composiciones de plaquetas con patogeno inactivado.
MX2019001053A (es) Inhibidores de antigeno de la membrana especifico para la prostata (psma) quelados.
MX2020004414A (es) Compuestos y uso de los mismos en la expansion de celulas madre y/o celulas progenitoras.
CO2021007172A2 (es) Sales cristalinas de un inhibidor de calicreína plasmática
CO2022002392A2 (es) Síntesis de un inhibidor de calicreína plasmática a escala de proceso
CL2024000248A1 (es) Composiciones y métodos para anticuerpos anti-pacap